Neutralization of virus infectivity by antibodies is an important component of immunity to several virus infections. Here, the immunochemical basis for the action of neutralizing antibodies, and what role their induction of conformational changes in the antigen might play, is reviewed. Theories of the mechanisms by which antibodies neutralize virus infectivity in vitro are also presented. The theoretical and empirical foundation of the hypothesis that viruses are neutralized by a single antibody per virion is critically reviewed. The relationship between antibody occupancy on virions and the mechanism of neutralization is explored. Examples of neutralization mediated through antibody interference with virus attachment and entry are discussed and test implications of refined theories of neutralization by antibody coating of virions are formulated.
ArmstrongS. J.,
DimmockN. J.1992; Neutralization of influenza virus by low concentrations of hemagglutinin-specific polymeric immunoglobulin A inhibits viral fusion activity, but activation of the ribonucleoprotein is also inhibited. Journal of Virology 66:3823–3832
ArmstrongS. J.,
DimmockN. J.1996; Varying temperature-dependence of post-attachment neutralization of human immunodeficiency virus type 1 by monoclonal antibodies to gp120: identification of a very early fusion-independent event as a neutralization target. Journal of General Virology 77:1397–1402
ArmstrongS. J.,
McInerneyT. L.,
McLainL.,
WahrenB.,
HinkulaJ.,
LeviM.,
DimmockN. J.1996; Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1. Journal of General Virology 77:2931–2941
BachmannM. F.,
KundigT. M.,
KalbererC. P.,
HengartnerH.,
ZinkernagelR. M.1994; How many specific B cells are needed to protect against a virus?. Journal of Immunology 152:4235–4241
BachmannM. F.,
KalinkeU.,
AlthageA.,
FreerG.,
BurkhartC.,
RoostH.,
AguetM.,
HengartnerH.,
ZinkernagelR. M.1997; The role of antibody concentration and avidity in antiviral protection. Science 276:2024–2027
BeirnaertE.,
De ZutterS.,
JanssensW.,
van der GroenG.2001; Potent broad cross-neutralizing sera inhibit attachment of primary HIV-1 isolates (groups m and o) to peripheral blood mononuclear cells. Virology 281:305–314
BizebardT.,
Berbey-MartinC.,
FleuryD.,
GigantB.,
BarrereB.,
SkehelJ. J.,
KnossowM.2001; Structural studies on viral escape from antibody neutralization. Current Topics in Microbiology and Immunology 260:55–64
BooyF. P.,
RodenR. B.,
GreenstoneH. L.,
SchillerJ. T.,
TrusB. L.1998; Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 Å resolution. Journal of Molecular Biology 281:95–106
BrioenP.,
ThomasA. A.,
BoeyeA.1985b; Lack of quantitative correlation between the neutralization of poliovirus and the antibody-mediated pI shift of the virions. Journal of General Virology 66:609–613
BuggeT. H.,
LindhardtB. O.,
HansenL. L.,
KuskP.,
HulgaardE.,
HolmbackK.,
KlasseP. J.,
ZeuthenJ.,
UlrichK.1990; Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp41, defined by a human monoclonal antibody. Journal of Virology 64:4123–4129
BurnetF. M.,
KeoghE. V.,
LushD.1937; The immunological reactions of the filterable viruses. Australian Journal of Experimental Biology and Medical Science 15:227–368
BurtonD. R.,
ParrenP. W.2000; Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection?. Nature Medicine 6:123–125
BurtonD. R.,
PyatiJ.,
KoduriR.,
SharpS. J.,
ThorntonG. B.,
ParrenP. W.,
SawyerL. S.,
HendryR. M.,
DunlopN.,
NaraP. L.and others1994; Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024–1027
BurtonD. R.,
SaphireE. O.,
ParrenP. W.2001; A model for neutralization of viruses based on antibody coating of the virion surface. Current Topics in Microbiology and Immunology 260:109–143
CavaciniL. A.,
EmesC. L.,
PowerJ.,
DesharnaisF. D.,
DuvalM.,
MontefioriD.,
PosnerM. R.1995; Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody. Journal of Immunology 155:3638–3644
CheZ.,
OlsonN. H.,
LeippeD.,
LeeW. M.,
MosserA. G.,
RueckertR. R.,
BakerT. S.,
SmithT. J.1998; Antibody-mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus–Fab complexes. Journal of Virology 72:4610–4622
ColonnoR. J.,
CallahanP. L.,
LeippeD. M.,
RueckertR. R.,
TomassiniJ. E.1989; Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments. Journal of Virology 63:36–42
DulbeccoR.,
VogtM.,
StricklandA. G. R.1956; A study of the basic aspects of neutralization. Two animal viruses: Western equine encephalitis virus and poliomyelitis virus. Virology 2:162–205
EdwardsM. J.,
DimmockN. J.2000; Two influenza A virus-specific Fabs neutralize by inhibiting virus attachment to target cells, while neutralization by their IgGs is complex and occurs simultaneously through fusion inhibition and attachment inhibition. Virology 278:423–435
EdwardsM. J.,
DimmockN. J.2001a; Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event. Journal of Virology 75:10208–10218
EdwardsM. J.,
DimmockN. J.2001b; A haemagglutinin (HA1)-specific Fab neutralizes influenza A virus by inhibiting fusion activity. Journal of General Virology 82:1387–1395
EminiE. A.,
OstapchukP.,
WimmerE.1983; Bivalent attachment of antibody onto poliovirus leads to conformational alteration and neutralization. Journal of Virology 48:547–550
EpaV. C.,
ColmanP. M.2001; Shape and electrostatic complementarity at viral antigen–antibody complexes. Current Topics in Microbiology and Immunology 260:45–53
FoutsT. R.,
BinleyJ. M.,
TrkolaA.,
RobinsonJ. E.,
MooreJ. P.1997; Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. Journal of Virology 71:2779–2785
FryE. E.,
LeaS. M.,
JacksonT.,
NewmanJ. W.,
EllardF. M.,
BlakemoreW. E.,
Abu-GhazalalehR.,
SamuelA.,
KingA. M.,
StuartD. I.1999; The structure and function of a foot-and-mouth disease virus-oligosaccharide receptor complex. EMBO Journal 18:543–554
GnannJ. W.Jr,
NelsonJ. A.,
OldstoneM. B.1987; Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. Journal of Virology 61:2639–2641
GradyL. J.,
KinchW.1985; Two monoclonal antibodies against La Crosse virus show host-dependent neutralizing activity. Journal of General Virology 66:2773–2776
GreenspanN. S.2001a; Affinity, complementarity, cooperativity, and specificity in antibody recognition. Current Topics in Microbiology and Immunology 260:65–85
GreenspanN. S.,
CooperL. J.1995; Complementarity, specificity and the nature of epitopes and paratopes in multivalent interactions. Immunology Today 16:226–230
HewatE. A.,
VerdaguerN.,
FitaI.,
BlakemoreW.,
BrookesS.,
KingA.,
NewmanJ.,
DomingoE.,
MateuM. G.,
StuartD. I.1997; Structure of the complex of a Fab fragment of a neutralizing antibody with foot-and-mouth disease virus: positioning of a highly mobile antigenic loop. EMBO Journal 16:1492–1500
HewatE. A.,
MarlovitsT. C.,
BlaasD.1998; Structure of a neutralizing antibody bound monovalently to human rhinovirus 2. Journal of Virology 72:4396–4402
HoD. D.,
SarngadharanM. G.,
HirschM. S.,
SchooleyR. T.,
RotaT. R.,
KennedyR. C.,
ChanhT. C.,
SatoV. L.1987; Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. Journal of Virology 61:2024–2028
IcenogleJ.,
ShiwenH.,
DukeG.,
GilbertS.,
RueckertR.,
AndereggJ.1983; Neutralization of poliovirus by a monoclonal antibody: kinetics and stoichiometry. Virology 127:412–425
JerneN. K.,
AvegnoP.1956; The development of the phage-inactivating properties of serum during the course of specific immunization of an animal: reversible and irreversible inactivation. Journal of Immunology 76:200–208
KabatD.,
KozakS. L.,
WehrlyK.,
ChesebroB.1994; Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. Journal of Virology 68:2570–2577
KilbourneE. D.,
LaverW. G.,
SchulmanJ. L.,
WebsterR. G.1968; Antiviral activity of antiserum specific for an influenza virus neuraminidase. Journal of Virology 2:281–288
KingsfordL.,
BoucqueyK. H.,
CardosoT. P.1991; Effects of specific monoclonal antibodies on La Crosse virus neutralization: aggregation, inactivation by Fab fragments, and inhibition of attachment to baby hamster kidney cells. Virology 180:591–601
KlasseP. J.1996; Physico-chemical analysis of the humoral immune response to HIV-1: quantification of antibodies, their binding to viral antigens and neutralization of viral infectivity. In HIV Molecular Immunology Database pp 22–52 Edited by
KorberB.,
WalkerB.,
KoupR.,
MooreJ.,
HaynesB.,
MyersG.
Los Alamos, New Mexico: Los Alamos National Laboratory, Theoretical Biology and Biophysics;
KlasseP. J.,
MooreJ. P.1996; Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. Journal of Virology 70:3668–3677
KlasseP. J.,
McKeatingJ. A.,
SchuttenM.,
ReitzM. S.Jr,
Robert-GuroffM.1993; An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 [HXB2-Env: Ala(→Thr)] decreases viral neutralization by monoclonal antibodies to the CD4-binding site. Virology 196:332–337
KleinM.,
SchoppelK.,
AmvrossiadisN.,
MachM.1999; Strain-specific neutralization of human cytomegalovirus isolates by human sera. Journal of Virology 73:878–886
KwongP. D.,
WyattR.,
RobinsonJ.,
SweetR. W.,
SodroskiJ.,
HendricksonW. A.1998; Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648–659
KwongP. D.,
WyattR.,
MajeedS.,
RobinsonJ.,
SweetR. W.,
SodroskiJ.,
HendricksonW. A.2000a; Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure, Folding and Design 8:1329–1339
KwongP. D.,
WyattR.,
SattentauQ. J.,
SodroskiJ.,
HendricksonW. A.2000b; Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. Journal of Virology 74:1961–1972
LayneS. P.,
MergesM. J.,
SpougeJ. L.,
DemboM.,
NaraP. L.1991; Blocking of human immunodeficiency virus infection depends on cell density and viral stock age. Journal of Virology 65:3293–3300
LiQ.,
YafalA. G.,
LeeY. M.,
HogleJ.,
ChowM.1994; Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results form reversible exposure of these sequences at physiological temperature. Journal of Virology 68:3965–3970
LiL.,
CoelinghK. L.,
BrittW. J.1995; Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H. Journal of Virology 69:6047–6053
LinsleyP. S.,
LedbetterJ. A.,
Kinney-ThomasE.,
HuS. L.1988; Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the Env protein of human immunodeficiency virus type 1. Journal of Virology 62:3695–3702
LuS.,
PutneyS. D.,
RobinsonH. L.1992; Human immunodeficiency virus type 1 entry into T cells: more-rapid escape from an anti-V3 loop than from an antireceptor antibody. Journal of Virology 66:2547–2550
McDougalJ. S.,
KennedyM. S.,
OrloffS. L.,
NicholsonJ. K. A.,
SpiraT. J.1996; Mechanisms of human immunodeficiency virus type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody. Journal of Virology 69:5236–5245
McInerneyT. L.,
McLainL.,
ArmstrongS. J.,
DimmockN. J.1997; A human IgG1 (b12) specific for the CD4-binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event. Virology 233:313–326
MandelB.1976; Neutralization of poliovirus: a hypothesis to explain the mechanism and the one-hit character of the neutralization reaction. Virology 69:500–510
MondorI.,
MoulardM.,
UgoliniS.,
KlasseP. J.,
HoxieJ.,
AmaraA.,
DelaunayT.,
WyattR.,
SodroskiJ.,
SattentauQ. J.1998a; Interactions among HIV gp120, CD4, and CXCR4: dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH-and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies. Virology 248:394–405
MondorI.,
UgoliniS.,
SattentauQ. J.1998b; Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. Journal of Virology 72:3623–3634
MooreJ. P.,
ParrenP. W.,
BurtonD. R.2001; Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. Journal of Virology 75:5721–5729
ParryN.,
FoxG.,
RowlandsD.,
BrownF.,
FryE.,
AcharyaR.,
LoganD.,
StuartD.1990; Structural and serological evidence for a novel mechanism of antigenic variation in foot-and-mouth disease virus. Nature 347:569–572
PosseeR. D.,
SchildG. C.,
DimmockN. J.1982; Studies on the mechanism of neutralization of influenza virus by antibody: evidence that neutralizing antibody (anti-haemagglutinin) inactivates influenza virus in vivo by inhibiting virion transcriptase activity. Journal of General Virology 58:373–386
RauxH.,
CoulonP.,
LafayF.,
FlamandA.1995; Monoclonal antibodies which recognize the acidic configuration of the rabies glycoprotein at the surface of the virion can be neutralizing. Virology 210:400–408
RizzutoC. D.,
SodroskiJ. G.1997; Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. Journal of Virology 71:4847–4851
RodenR. B.,
WeissingerE. M.,
HendersonD. W.,
BooyF.,
KirnbauerR.,
MushinskiJ. F.,
LowyD. R.,
SchillerJ. T.1994; Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. Journal of Virology 68:7570–7574
RoivainenM.,
PiirainenL.,
RysaT.,
NarvanenA.,
HoviT.1993; An immunodominant N-terminal region of VP1 protein of poliovirus that is buried in the crystal structure can be exposed in solution. Virology 195:762–765
RoostH. P.,
BachmannM. F.,
HaagA.,
KalinkeU.,
PliskaV.,
HengartnerH.,
ZinkernagelR. M.1995; Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity. Proceedings of the National Academy of Sciences, USA 92:1257–1261
RuggeriF. M.,
GreenbergH. B.1991; Antibodies to the trypsin cleavage peptide VP8 neutralize rotavirus by inhibiting binding of virions to target cells in culture. Journal of Virology 65:2211–2219
RuppachH.,
NaraP.,
RaudonatI.,
ElanjikalZ.,
Rubsamen-WaigmannH.,
DietrichU.2000; Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes. Journal of Virology 74:5403–5411
SaphireE. O.,
ParrenP. W.,
PantophletR.,
ZwickM. B.,
MorrisG. M.,
RuddP. M.,
DwekR. A.,
StanfieldR. L.,
BurtonD. R.,
WilsonI. A.2001; Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design. Science 293:1155–1159
SattentauQ. J.,
MooreJ. P.1995; Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. Journal of Experimental Medicine 182:185–196
ScharfO.,
GoldingH.,
KingL. R.,
EllerN.,
FrazierD.,
GoldingB.,
ScottD. E.2001; Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1. Journal of Virology 75:6558–6565
SchønningK.,
LundO.,
LundO. S.,
HansenJ. E.1999; Stoichiometry of monoclonal antibody neutralization of T-cell line-adapted human immunodeficiency virus type 1. Journal of Virology 73:8364–8370
SkehelJ. J.,
WileyD. C.2000; Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annual Review of Biochemistry 69:531–569
SmithT. J.2001; Antibody interactions with rhinovirus: lessons for mechanisms of neutralization and the role of immunity in viral evolution. Current Topics in Microbiology and Immunology 260:1–29
SmithT. J.,
OlsonN. H.,
ChengR. H.,
HansongL.,
ChaseE. S.,
LeeW. M.,
LeippeD. M.,
MosserA. G.,
RueckertR. R.,
BakerT. S.1993; Structure of human rhinovirus complexed with Fab fragments from a neutralizing antibody. Journal of Virology 67:1148–1158
SpenlehauerC.,
KirnA.,
AubertinA. M.,
MoogC.2001; Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition. Journal of Virology 75:2235–2245
ThaliM.,
MooreJ. P.,
FurmanC.,
CharlesM.,
HoD. D.,
RobinsonJ.,
SodroskiJ.1993; Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. Journal of Virology 67:3978–3988
ThaliM.,
MacArthurC.,
FurmanC.,
CavaciniL.,
PosnerM.,
RobinsonJ.,
SodroskiJ.1994; Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change. Journal of Virology 68:674–680
UgoliniS.,
MondorI.,
ParrenP. W.,
BurtonD. R.,
TilleyS. A.,
KlasseP. J.,
SattentauQ. J.1997; Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. Journal of Experimental Medicine 186:1287–1298
VerdaguerN.,
SchoehnG.,
OchoaW. F.,
FitaI.,
BrookesS.,
KingA.,
DomingoE.,
MateuM. G.,
StuartD.,
HewatE. A.1999; Flexibility of the major antigenic loop of foot-and-mouth disease virus bound to a Fab fragment of neutralising antibody: structure and neutralisation. Virology 255:260–268
VerrierF.,
NadasA.,
GornyM. K.,
Zolla-PaznerS.2001; Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. Journal of Virology 75:9177–9186
VzorovA. N.,
CompansR. W.2000; Effect of the cytoplasmic domain of the simian immunodeficiency virus envelope protein on incorporation of heterologous envelope proteins and sensitivity to neutralization. Journal of Virology 74:8219–8225
WebsterR. G.,
LaverW. G.1967; Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus. Journal of Immunology 99:49–55
WetzK.,
WillingmannP.,
ZeichhardtH.,
HabermehlK. O.1986; Neutralization of poliovirus by polyclonal antibodies requires binding of a single IgG molecule per virion. Archives of Virology 91:207–220
WilsonC.,
ReitzM. S.Jr,
AldrichK.,
KlasseP. J.,
BlombergJ.,
GalloR. C.,
Robert-GuroffM.1990; The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope. Journal of Virology 64:3240–3248
ZebedeeS. L.,
LambR. A.1988; Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. Journal of Virology 62:2762–2772